Plecanatide vs Lixisenatide
Head-to-head comparison of Plecanatide (Plecanatide) and Lixisenatide (Exendin-4-derived GLP-1 receptor agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Plecanatide | Lixisenatide |
|---|---|---|
| Category | Gastrointestinal | Weight Management |
| Full Name | Plecanatide | Exendin-4-derived GLP-1 receptor agonist |
| Molecular Weight | Approx. 1620 Da | 4858 Da |
| Half-Life | Local intestinal action; systemic half-life not clinically meaningful | 2-4 hours |
| Amino Acids | 16 | 44 |
| Typical Dose | 3 mg once daily | 10-20 mcg daily |
| Route | Oral | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 350 | 400 |
| Research Status | Clinical | Approved |
Plecanatide Benefits
- ✓improves-stool-frequency
- ✓supports-fluid-secretion
- ✓may-reduce-constipation
- ✓local-gut-action
Lixisenatide Benefits
- ✓postprandial glucose control
- ✓modest weight loss
- ✓appetite reduction
- ✓short-acting option
Plecanatide Dosing
3 mg PO daily|take with or without food|avoid when dehydrated
Lixisenatide Dosing
10 mcg SC daily for 14 days|Increase to 20 mcg daily|Inject before the first meal of the day
Plecanatide Side Effects
- ⚠diarrhea
- ⚠abdominal-discomfort
- ⚠nausea
Lixisenatide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠hypoglycemia when combined with insulin
Research Overview
Plecanatide
Clinical trials show plecanatide improves constipation outcomes with a generally favorable tolerability profile. Like linaclotide, it acts locally in the intestinal lumen via GC-C signaling rather than systemic hormone effects.
Lixisenatide
Lixisenatide produces small but measurable weight loss in diabetes trials while improving postprandial glucose excursions. Its shorter half-life makes it a useful reference compound for first-generation incretin mimetics.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.